Ein Schöns Geystlichs Lied : Darinn wirt angezeygt wie die welt das wort Gottes yetzt so gering achtet, ...

In Fraktur

Ein Gespräch zweier jüdischen Freunde über das Wort Gottes

[J.A.H.]

Grundriss einer biblischen Keryktik, oder einer Anweisung, durch das Wort Gottes sich zur Predigtkunst zu bilden.

Mode of access: Internet.

Sieg der Reform und des Geistes. Abschiedspredigt über Jesaias 40,8 : "es dorret das Gras; es welket die Blume; doch unseres Gottes Wort besteht in Ewigkeit"

gehalten in der Hauptsynagoge zu Frankfurt a. M. am Trostsabbath 5622 (9. August 1862) von Leopold Stein

Notwendige Erinnerung/ auff dz schreckliche Fewerzeichen/ So den 10. Septembris deß jetzlauffenden 1580. Jahrs am Himmel gesehen worden/ sampt einer gründlichen gewissen Rechnung aus Gottes Wort/ daß das Ende der Welt und der Jüngste tag nahe für der Thüren

Iacobus Colerus D.

Des hocherleuchteten sel. Johann Arndts, General-Superintendentens des Fürstenthums Lüneburg, Fünff geistreiche Bücher vom wahren Christenthum : welche handeln von heilsamer Busse, hertzlicher Reue und Leid über die Sünde, und wahrem Glauben, auch heiligem Leben und Wandel der Wahren Christen, auch wie ein wahrer Christ Sünde, Tod, Teufel, Hölle, Welt, Creutz und alle Trübsal, durch den Glauben, Gebet, Gedult, Gottes Wort und himmlischen Trost überwinden sol : und dasselbe alles in Christo Jesu : welchen noch beygefüget drey andere kleine Bücher, welche zu des sel. Johann Arndts wahren Christenthum gehörig, als I. Die Wiederholung und Verantwortung der Lehre vom wahren Christenthum, II. Zwey Sendschreiben an gute Freunde, die Bücher des wahren Christenthums betreffend, III. Bedencken über Tauleri Teutsche Theologie, wie hoch solche zu halten ...

Includes index.

Von dem grünenden/ wachsenden/ welckenden und abfallenden Laub : Eine Christliche unnd in Gottes Wort gegründte Leichpredig/ bey der traurigen Begräbnuß weyland des ... Herrn Georgen Lauben von Augspurg ... welcher den 10. Tag Nouembris 1597 ... verschiden ...

Durch Iacobum Rülichium von Augsburg/ Pfarrer daselbß

St. John’s wort and Kava in treating major depressive disorder with comorbid anxiety : a randomised double-blind placebo-controlled pilot trial

Objective - We report the first randomised controlled trial (RCT) using a combination of St. John’s wort (SJW) and Kava for the treatment of major depressive disorder (MDD) with comorbid anxiety. Methods - Twenty-eight adults with MDD and co-occurring anxiety were recruited for a double-blind RCT. After a placebo run-in of 2 weeks, the trial had a crossover design testing SJW and Kava against placebo over two controlled phases, each of 4 weeks. The primary analyses used intention-to-treat and completer analyses. Results - On both intention-to-treat ( p¼0.047) and completer analyses ( p¼0.003), SJW and Kava gave a significantly greater reduction in self-reported depression on the Beck Depression Inventory (BDI-II) over placebo in the first controlled phase. However, in the crossover phase, a replication of those effects in the delayed medication group did not occur. Nor were there significant effects on anxiety or quality of life. Conclusion - There was some evidence of antidepressant effects using SJW and Kava in a small sample with comorbid anxiety. Possible explanations for the absence of anxiolysis may include a potential interaction with SJW, the presence of depression, or an inadequate dose of Kava.

Kava and St. John's wort : current evidence for use in mood and anxiety disorders

Background: Mood and anxiety disorders pose significant health burdens on the community. Kava and St John’s wort (SJW) are the most commonly used herbal medicines in the treatment of anxiety and depressive disorders, respectively. Objectives: To conduct a comprehensive review of kava and SJW, to review any evidence of efficacy, mode of action, pharmacokinetics, safety and use in Major Depressive Disorder (MDD), Bipolar Disorder (BP), Seasonal Affective Disorder (SAD), Generalized Anxiety Disorder (GAD), Social Phobia (SP), Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), and Post Traumatic Stress Disorder (PTSD). Methods: A systematic review was conducted using the electronic databases MEDLINE, CINAHL, and The Cochrane Library during late 2008. The search criteria involved mood and anxiety disorder search terms in combination with kava, Piper methysticum, kavalactones, St John’s wort, Hypericum perforatum, hypericin and hyperforin. Additional search criteria for safety, pharmacodynamics , and pharmacokinetics was employed. A subsequent forward search was conducted of the papers using Web of Science cited reference search. Results: Current evidence supports the use of SJW in treating mild-moderate depression, and for kava in treatment of generalized anxiety. In respect to the other disorders, only weak preliminary evidence exists for use of SJW in SAD. Currently there is no published human trial on use of kava in affective disorders, or in OCD, PTSD, PD or SP. These disorders constitute potential applications that warrant exploration. Conclusions: Current evidence for herbal medicines in the treatment of depression and anxiety only supports the use of Hypericum perforatum for depression, and Piper methysticum for generalized anxiety.

Potential of St John's Wort for the treatment of depression : the economic perspective

The burden of rising health care expenditures has created a demand for information regarding the clinical and economic outcomes associated with complementary and alternative medicines. Meta-analyses of randomized controlled trials have found Hypericum perforatum preparations to be superior to placebo and similarly effective as standard antidepressants in the acute treatment of mild to moderate depression. A clear advantage over antidepressants has been demonstrated in terms of the reduced frequency of adverse effects and lower treatment withdrawal rates, low rates of side effects and good compliance, key variables affecting the cost-effectiveness of a given form of therapy. The most important risk associated with use is potential interactions with other drugs, but this may be mitigated by using extracts with low hyperforin content. As the indirect costs of depression are greater than five times direct treatment costs, given the rising cost of pharmaceutical antidepressants, the comparatively low cost of Hypericum perforatum extract makes it worthy of consideration in the economic evaluation of mild to moderate depression treatments.